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TO THE EDITOR
A recent article published by Okamoto
et al. (2006) in the Journal of Investiga-
tive Dermatology showed that the
polymorphism 61A4G in the epider-
mal growth factor (EGF) gene was
significantly associated with bad prog-
nosis of malignant melanoma and
could be a potential marker for disease
severity and predict earlier progression
of malignant melanoma. Moreover,
with regards to malignant melanoma
risk and to Breslow thickness (a mela-
noma progression indicator), conflict-
ing results were found in previous
published reports (Shahbazi et al.,
2002; McCarron et al., 2003; Amend
et al., 2004; James et al., 2004).
The 61A4G polymorphism in the 50
untranslated region of EGF was re-
ported to affect EGF production in
activated cultured peripheral blood
mononuclear cells for the first time by
Shahbazi et al. (2002). However, no
team investigated the effect of this
polymorphism on EGF production in
vivo, in the plasma of healthy indivi-
duals. Thus, the current study aimed to
assess the 61A4G polymorphism effect
on plasma EGF concentration in
healthy adults and children, first by an
association study, second by familial
correlations, and final by a variance
component analysis.
This work was carried out on a
random sub-sample of 197 nuclear
families from the STANISLAS cohort
(Siest et al., 1998) and composed of two
parents and at least one child (Table 1).
Subjects were free from chronic ill-
nesses. Each participant or participant’s
parent or legal guardian gave written
informed consent for participation. The
study adheres to the Declaration of
Helsinki Principles and was approved
by the local medical ethics committee
of Nancy (France). Quantification of
plasma EGF concentration was per-
formed by using a biochip array analy-
zer (Evidences) (Berrahmoune et al.,
2006). The 61A4G EGF polymorphism
was in Hardy–Weinberg equilibrium
and genotypic frequencies were
36.2% for AA, 47.6% for AG, and
16.2% for GG in the whole group.
These frequencies did not differ signifi-
cantly from those reported in the
summarized Table 1 by Okamoto
et al. (2006). In regression analysis,
the 61A4G polymorphism was not
related to plasma EGF concentration
by using crude or adjusted values for
related covariates previously found
(Berrahmoune et al., 2006) (age, anti-
inflammatory agent use, glucose con-
centration, and monocyte and platelet
counts) in the global sample and what-
ever the sex-by-generation groups.
Using a previously described power
calculation method (Tre´goue¨t et al.,
2001), we found that our study was
adequate to evaluate 2% and more of
heritability (percent of variance ex-
plained by the polymorphism), achiev-
ing a statistical power of 80% at the 5%
probability level (P-value).
Familial aggregation analysis
showed significant correlation coeffi-
cients for spouse, parent–offspring, and
offspring–offspring pairs: 0.254, 0.285,
and 0.247 (Pp0.001), respectively, indi-
cating a strong familial resemblance.
Relative variances attributable to addi-
tive genetics, household environment,
and residual factors (including assay
imprecision) were 9.3, 23.2, and 67.5%
of total variance, respectively. In addi-
tion, the 61A4G polymorphism signif-
icantly modified neither the estimate of
family correlations nor the genetic
component. A previous study (Pantsu-
laia et al., 2004) found a more im-
portant genetic component (48.4%).
This study provides early evidence of
the effect of the 61A4G polymorphism
in relation to plasma EGF concentration
in healthy individuals. Under physiolo-
gical circumstances, this polymorphism
was not associated with plasma EGF
concentrations in our study, whereas
effects were shown in in vitro stimu-
lated cells (Shahbazi et al., 2002) and in
malignant gliomas (Bhowmick et al.,
2004). Specific transcription factors
may recognize the EGF promoter at
the 61A4G polymorphism site in
particular conditions, such as activation
of cells or cancerous growth that leads
to the increase of EGF production by
these cells and consequently, to raised
its concentration in plasma.
These observations may help to
explain why this polymorphism is not
a good predictor of melanoma thick-
ness at initial presentation, whereas it
does appear to be a predictor of
melanoma metastasis and survival.
In conclusion, despite the fact that
additive genetic components account
for 10% (this study) to 48% (Pantsulaia
et al., 2004) of total plasma EGF
concentration variability, the 61A4G
polymorphism is not associated with
this trait and does not significantly
explain this component under physio-
logical circumstances.
Further work is needed to confirm
and expand the clinical relevance of
both 61A4G polymorphism and EGF
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Abbreviation: EGF, epidermal growth factor
concentration (in tumors and plasma),
and the implication of putative tran-
scription factors, in risk and progression
of malignant melanoma.
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Table 1. Characteristics of the population1
Adults Children
Men (n=197) Women (n=197) Boys (n=239) Girls (n=226) P-value2
Age (years) 44.9 (4.0) 43.1 (4.1) 16.2 (4.1) 16.3 (4.1) p0.0001
BMI (kg/m2) 25.6 (3.2) 24.1 (4.3) 20.3 (3.2) 20.5 (2.9) —
Tobacco consumption (cig/day) 4.7 (9.6) 2.4 (6.4) 2.2 (5.2) 1.3 (4.0) p0.0001
Alcohol consumption (g/day) 21.9 (25.7) 6.1 (10.7) 2.1 (6.4) 0.91 (2.6) p0.0001
Glucose (mmol/l) 5.14 (0.537) 4.87 (0.475) 4.80 (0.463) 4.69 (0.432) p0.0001
Leukocyte count (109/l) 6.55 (1.64) 6.84 (1.50) 6.58 (1.74) 6.96 (1.62) 0.019
Lymphocyte count (109/l) 1.99 (0.56) 1.99 (0.59) 2.27 (0.59) 2.31 (0.57) p0.0001
Monocyte count (109/l) 0.559 (0.151) 0.545 (0.151) 0.609 (0.180) 0.582 (0.156) 0.0002
Platelet count (109/l) 239.2 (51.6) 250.2 (55.3) 240.7 (49.97) 257.5 (52.1) 0.0006
Anti-inflammatory use (%) 7% 4.5% 0.8% 4.4% 0.011
EGF (pg/ml)3,4 11.3 (4.14–31.1) 11.5 (4.31–30.9) 11.2 (4.48–27.8) 10.8 (4.64–25.1) NS
BMI, body mass index; EGF, epidermal growth factor; NS, not significant.
1Arithmetic means7SD or percent.
2Global ANOVA across the four groups. NS: (P40.05).
3Statistic tests on log10-transformed values.
4Geometric means (range of 1 SD).
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